Navigation Links
CyVek, Inc. Secures $5.5 Million in Series D Financing
Date:2/4/2013

WALLINGFORD, Conn., Feb. 4, 2013 /PRNewswire/ -- CyVek, Inc., an innovator in multi-analyte immunoassay technology, announced today that it has secured a Series D round of financing in the amount of $5.5 million.  Connecticut Innovations and a group of private investors participated in the round.

The Series D funding enables the company to create the infrastructure needed to commercialize its novel immunoassay technology, CyPlex™, an integrated test system which includes a proprietary microfluidic cartridge that allows the analysis of multiple biomarkers from very small amounts of biological samples.  This technology has broad appeal in research and clinical applications.  Initially the CyVek system will be used in biomarker analysis in life sciences, drug discovery and clinical research.  CyVek is currently in the beta testing phase.

Per Hellsund , CyVek founder, President and CEO, commented, "We are very pleased to have closed our Series D financing. The funding provided by our investors will enable us to complete development related activities and put together the team and infrastructure required to commercialize.  CyPlex™ continues to demonstrate excellent reproducibility coupled with unprecedented ease of use and will provide exceptional value to researchers and clinicians alike.  We have had extremely positive feedback from early customers and this validates our vision of CyVek fulfilling unmet needs in basic research, translational research and clinical diagnostics."

CyVek was formed in 2010 and is led by an experienced team of researchers and business executives who have developed and commercialized technologies, launched products, driven sales, negotiated partnerships, and led companies from start up to liquidity events.

About CyVek Inc.

CyVek is a privately funded biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays.  CyVek's  CyPlex™ is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings.  For more information about CyVek, please call 203-679-0395 or visit us on the web at www.cyvek.com

Contact:
Sheila Burns
203-679-0395


'/>"/>
SOURCE CyVek, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
2. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
3. Unisense FertiliTech A/S Secures 24 Million USD in New Capital Investment
4. Biomatrica Secures Financing of $5 Million
5. SurgiQuest, Inc. Secures Additional $18.5 Million Funding to Fuel Worldwide Expansion and Commercialization Efforts
6. Zafgen Secures $21 Million in Series D Financing
7. Flexion Therapeutics Secures $20 Million in Series B Financing
8. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
9. ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
10. BioMotiv Secures $21 million in Initial Funding
11. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... 2017  Sensus Healthcare, Inc. (NASDAQ: ... the treatment of non-melanoma skin cancers and other ... therapy, today announced that it will report its ... on Thursday, February 2, 2017 after the market close. ... call with the investment community on Thursday, February 2, ...
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at ... Oat is recognized globally as one of the healthiest cereals, XieQingkui, the founder of ... a move to sow the seed of good karma. Buddhism spirit featuring benevolence and ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, ... experience the freedom of recovery, they often feel shame for having struggled with an ... disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” -- ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body care ... announced the company had a successful visit to the 2017 ECRM Diet, Vitamin & ... that work in the nutritional, sports and health industries a chance to meet in ...
(Date:1/20/2017)... , ... January 20, 2017 , ... International Protein, a ... and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton Head, ... nutritional scientist who was determined to create a line of products that would elevate ...
(Date:1/20/2017)... ... , ... “The Angel”: a heartwarming and earnest tale of faith and ... children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional ... writer. , When asked of her new book, Marjorie says, “‘The Angel’ was written ...
Breaking Medicine News(10 mins):